A Systematic Review of Major Advances in Breast Cancer Therapeutics in 2025: Synthesis of Conference and Published Evidence - PubMed
6 hours ago
- #precision-medicine
- #breast-cancer
- #systematic-review
- 2025 marked significant advances in breast cancer therapeutics, with new standards of care established across all molecular subtypes.
- Adjuvant CDK4/6 inhibitors showed overall survival benefits in HR+/HER2- early breast cancer (monarchE trial).
- Trastuzumab deruxtecan (T-DXd) became a new standard for high-risk HER2+ early and metastatic breast cancer (DESTINY-Breast trials).
- TROP2-directed ADCs validated as first-line therapy for metastatic triple-negative breast cancer (ASCENT-03, BEGONIA trials).
- Liquid biopsy-guided therapy switching demonstrated improved progression-free survival (SERENA-6 trial).
- Oral SERD imlunestrant showed efficacy in ESR1-mutated advanced breast cancer (EMBER-3 trial).
- Neoadjuvant carboplatin confirmed long-term survival benefits in early TNBC.
- Advances in HER2+ metastatic disease sequencing with tucatinib and T-DXd.
- Optimized adjuvant endocrine therapy supported for HER2+/HR+ early disease.
- Emergence of novel agents like PROTAC degraders, oral SERDs, and mutant-selective PI3K inhibitors.